Rezolute updates on ersodetug trials, FDA review, fiscal 2026 results
The company reported interim upLIFT progress, an ongoing FDA review of the sunRIZE congenital HI data, and $107.8 million in cash and investments as of June 30, 2026.
SEC filing
Latest
1 story